Quantitative assay for the detection of the V617F variant in the Janus kinase 2 (JAK2) gene using the Luminex xMAP technology

BMC Medical Genetics

Volumn 11, Issue 1, 2010, Pages

  Paradis, François W ^a   Simard, Raynald ^a   Gaudet, Daniel ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR RECEPTOR; HEMOPOIETIC GROWTH FACTOR; JANUS KINASE 2; MICROSPHERE; MUTANT PROTEIN;

ALLELE; ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DNA HYBRIDIZATION; ENZYME ACTIVITY; GENE IDENTIFICATION; GENE MAPPING; GENE TECHNOLOGY; GENETIC VARIABILITY; GENOMICS; HUMAN; MUTATIONAL ANALYSIS; POINT MUTATION; POLYMERASE CHAIN REACTION; QUANTITATIVE STUDY; AMINO ACID SUBSTITUTION; BLOOD; CHEMISTRY; DNA PROBE; GENETICS; METHODOLOGY; MYELOPROLIFERATIVE DISORDER; NUCLEIC ACID HYBRIDIZATION; NUCLEOTIDE SEQUENCE;

ALLELES; AMINO ACID SUBSTITUTION; DNA MUTATIONAL ANALYSIS; DNA PROBES; HUMANS; JANUS KINASE 2; MUTANT PROTEINS; MYELOPROLIFERATIVE DISORDERS; NUCLEIC ACID HYBRIDIZATION; POINT MUTATION; POLYMERASE CHAIN REACTION;

EID: 77950538708     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-11-54     Document Type: Article

References (28)

1. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7(4):387-97. 10.1016/j.ccr.2005.03.023, 15837627.
2. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000, 96(10):3343-56.
3. Reilly JT. Receptor tyrosine kinases in normal and malignant haematopoiesis. Blood Rev 2003, 17(4):241-8. 10.1016/S0268-960X(03)00024-9, 14556779.
4. Wadleigh M, DeAngelo DJ, Griffin JD, Stone RM. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood 2005, 105(1):22-30. 10.1182/blood-2003-11-3896, 15358622.
5. Rane SG, Reddy EP. Janus Kinases: components of multiple signaling pathways. Oncogene 2000, 19:5662-5679. 10.1038/sj.onc.1203925, 11114747.
6. Smith CA, Fan G. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. Hum Pathol 2008, 39(6):795-810. 10.1016/j.humpath.2008.02.004, 18538168.
7. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, . Cancer Genome Project Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365(9464):1054-61. Cancer Genome Project.
8. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434(7037):1144-8. 10.1038/nature03546, 15793561.
9. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352(17):1779-90. 10.1056/NEJMoa051113, 15858187.
10. Sidon P, El Housni H, Dessars B, Heimann P. The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 2006, 20(9):1622. 10.1038/sj.leu.2404292, 16775613.
11. Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B, Hanlon K, Hermans M, Richard C, Swierczek S, Ugo V, Carillo S, Harrivel V, Marzac C, Pietra D, Sobas M, Mounier M, Migeon M, Ellard S, Kröger N, Herrmann R, Prchal JT, Skoda RC, Hermouet S. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 2009, 94(1):38-45. 10.3324/haematol.13486, 2625411, 19001280.
12. Steensma DP. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006, 8(4):397-411. 10.2353/jmoldx.2006.060007, 1867618, 16931578.
13. Wolstencroft EC, Hanlon K, Harries LW, Standen GR, Sternberg A, Ellard S. Development of a quantitative real-time polymerase chain reaction assay for the detection of the JAK2 V617F mutation. J Mol Diagn 2007, 9(1):42-6. 10.2353/jmoldx.2007.060083, 1867420, 17251334.
14. Rapado I, Albizua E, Ayala R, Hernández JA, Garcia-Alonso L, Grande S, Gallardo M, Gilsanz F, Martinez-Lopez J. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. Ann Hematol 2008, 87(9):741-9. 10.1007/s00277-008-0512-x, 18575865.
15. Dunbar SA, Jacobson JW. Rapid screening for 31 mutations and polymorphisms in the cystic fibrosis transmembrane conductance regulator gene by Luminex xMAP suspension array. Methods Mol Med 2005, 114:147-71.
16. Caggana M, Conroy JM, Pass KA. Rapid, efficient method for multiplex amplification from filter paper. Hum Mutat 1998, 11(5):404-9. 10.1002/(SICI)1098-1004(1998)11:5<404::AID-HUMU8>3.0.CO;2-S, 9600459.
17. Dunbar SA. Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin Chim Acta 2006, 363(1-2):71-82. 10.1016/j.cccn.2005.06.023, 16102740.
18. Tan AY, Westerman DA, Dobrovic A. A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation. Am J Clin Pathol 2007, 127(6):977-81. 10.1309/1U61JVXTLPPQ7YP1, 17509995.
19. Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007, 136(5):745-51. 10.1111/j.1365-2141.2007.06497.x, 17313377.
20. Toyama K, Karasawa M, Yamane A, Irisawa H, Yokohama A, Saitoh T, Handa H, Matsushima T, Sawamura M, Miyawaki S, Murakami H, Nojima Y, Tsukamoto N. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. Br J Haematol 2007, 139(1):64-9. 10.1111/j.1365-2141.2007.06755.x, 17854308.
21. Bogani C, Guglielmelli P, Antonioli E, Pancrazzi A, Bosi A, Vannucchi AM. B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. Haematologica 2007, 92(2):258-9. 10.3324/haematol.10527, 17296581.
22. Delhommeau F, Dupont S, Tonetti C, Massé A, Godin I, Le Couedic JP, Debili N, Saulnier P, Casadevall N, Vainchenker W, Giraudier S. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 2007, 109(1):71-7. 10.1182/blood-2006-03-007146, 16954506.
23. Hermouet S, Dobo I, Lippert E, Boursier MC, Ergand L, Perrault-Hu F, Pineau D. Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F). Leukemia 2007, 21(5):1128-30.
24. Ohyashiki K, Hori K, Makino T, Ohyashiki JH. Automated JAK2V617F quantification using a magnetic filtration system and sequence-specific primer-single molecule fluorescence detection. Cancer Genet Cytogenet 2007, 179(1):19-24. 10.1016/j.cancergencyto.2007.07.008, 17981210.
25. Yoo JH, Park TS, Maeng HY, Sun YK, Kim YA, Kie JH, Cho EH, Song J, Lee KA, Suh B, Choi JR. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature. Cancer Genet Cytogenet 2009, 189(1):43-7. 10.1016/j.cancergencyto.2008.09.010, 19167611.
26. Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma 2008, 49(3):388-97. Review, 10.1080/10428190801895360, 18297515.
27. Ma W, Kantarjian H, Zhang X, Yeh CH, Zhang ZJ, Verstovsek S, Albitar M. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn 2009, 11(1):49-53. 10.2353/jmoldx.2009.080114, 2607565, 19074595.
28. Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 2008, 19(4):385-93. 10.1016/j.semcdb.2008.07.002, 18682296.